Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification of a Non-Gatekeeper Hot Spot for Drug-Resistant Mutations in mTOR Kinase.

Cell reports - 21 Apr 2015

Wu Tzung-Ju, Wang Xiaowen, Zhang Yanjie, Meng Linghua, Kerrigan John E, Burley Stephen K, Zheng X F Steven

Abstract excerpt

Protein kinases are therapeutic targets for human cancer. However, "gatekeeper" mutations in tyrosine kinases cause acquired clinical resistance, limiting long-term treatment benefits. mTOR is a key cancer driver and drug target. Numerous small-molecule mTOR kinase inhibitors have been developed, with some already in human clinical trials. Given our clinical experience with targeted therapeutics, acquired drug...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Line, Tumor
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Heterografts

Share to Mice, Nude

Share to Mutagenesis, Site-Directed

Share to Saccharomyces cerevisiae

Share to TOR Serine-Threonine Kinases

Source

Open in PubMed Open full text

Identifiers

PMID: 25865887
DOI: 10.1016/j.celrep.2015.03.040
PMCID: PMC4761412

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification of a Non-Gatekeeper Hot Spot for Drug-Resistant Mutations in mTOR Kinase.PMID 25865887Read ↗

Targeting Gatekeeper Mutations for Kinase Drug DiscoverySemantic proximity Read ↗

Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor.Semantic proximity Read ↗

Mammalian Target of Rapamycin (mTOR) Signalling Pathway-A Potential Target for Cancer Intervention: A Short OverviewSemantic proximity Read ↗

The resistance tetrad: amino acid hotspots for kinome-wide exploitation of drug-resistant protein kinase alleles.Semantic proximity Read ↗

A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity.Semantic proximity Read ↗

Targeting gain of function and resistance mutations in Abl and KIT by hybrid compound design.Semantic proximity Read ↗

mTOR pathway diseases: challenges and opportunities from bench to bedside and the mTOR nodeSemantic proximity Read ↗

Advances in protein kinase drug discovery through targeting gatekeeper mutations.Semantic proximity Read ↗

Landscape of drug-resistance mutations in kinase regulatory hotspotsSemantic proximity Read ↗

A general framework for inhibitor resistance in protein kinases.Semantic proximity Read ↗

Systematic Analysis of Tyrosine Kinase Inhibitor Response to RET Gatekeeper Mutations in Thyroid Cancer.Semantic proximity Read ↗

mTOR Inhibitors in Cancer: What Can We Learn from Exceptional Responses?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.